D. KANCA Et Al. , "Additive Antiatherogenic Effects of CETP rs708272 on Serum LDL Subfraction Levels in Patients with CHD Under Statin Therapy," BIOCHEMICAL GENETICS , vol.55, no.2, pp.168-182, 2017
KANCA, D. Et Al. 2017. Additive Antiatherogenic Effects of CETP rs708272 on Serum LDL Subfraction Levels in Patients with CHD Under Statin Therapy. BIOCHEMICAL GENETICS , vol.55, no.2 , 168-182.
KANCA, D., GORMUS, U., TOKAT, B., ERONAT, A., Bugra, Z., Ozturk, O., ... Yilmaz-Aydogan, H.(2017). Additive Antiatherogenic Effects of CETP rs708272 on Serum LDL Subfraction Levels in Patients with CHD Under Statin Therapy. BIOCHEMICAL GENETICS , vol.55, no.2, 168-182.
KANCA, D Et Al. "Additive Antiatherogenic Effects of CETP rs708272 on Serum LDL Subfraction Levels in Patients with CHD Under Statin Therapy," BIOCHEMICAL GENETICS , vol.55, no.2, 168-182, 2017
KANCA, D Et Al. "Additive Antiatherogenic Effects of CETP rs708272 on Serum LDL Subfraction Levels in Patients with CHD Under Statin Therapy." BIOCHEMICAL GENETICS , vol.55, no.2, pp.168-182, 2017
KANCA, D. Et Al. (2017) . "Additive Antiatherogenic Effects of CETP rs708272 on Serum LDL Subfraction Levels in Patients with CHD Under Statin Therapy." BIOCHEMICAL GENETICS , vol.55, no.2, pp.168-182.
@article{article, author={D KANCA Et Al. }, title={Additive Antiatherogenic Effects of CETP rs708272 on Serum LDL Subfraction Levels in Patients with CHD Under Statin Therapy}, journal={BIOCHEMICAL GENETICS}, year=2017, pages={168-182} }